<u>Title:</u> COVID-19 Outcomes Among Users of CD20 Inhibitors for Immune-Mediated Diseases:

A Comparative Cohort Study

<u>Authors:</u> Naomi J. Patel, MD*‡; Kristin M. D'Silva, MD, MPH*‡\$; Tiffany Y-T. Hsu, MD, PhD^{||}; Michael DiIorio, MD^{||}; Xiaoqing Fu, MS^{‡§}; Claire Cook, MPH^{‡§}; Lauren Prisco, BA^{||}; Lily Martin, BS^{||}; Kathleen M.M. Vanni, BA^{||}; Alessandra Zaccardelli, MS^{||}; Yuqing Zhang, ScD^{‡§}; Jeffrey A. Sparks, MD, MMSc^{†||}; Zachary S. Wallace, MD, MSc^{†‡§}

Affiliations:

[‡]Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, USA

§Clinical Epidemiology Program, Mongan Institute, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA

Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA, USA

All at Harvard Medical School, Boston, MA.

Supplement

Supplemental Table 1. Details of death following COVID-19 in immune-mediated cases treated with CD20 inhibitors and matched comparators.

	CD20 Inhibitor-Treated	Matched Comparator
	Immune-Mediated	Deaths (n=21)
	Case Deaths (n=12)	
Age, years, mean ± SD	69.0 ± 19.4	77.0 ± 11.7
Female, n (%)	5 (42)	6 (29)
Hospitalized within MGB, n (%)	11 (92)	20 (95)
Mechanically ventilated within MGB, n (%)	4 (33)	8 (38)
"Do not intubate" code status, n (%)	6 (50)	10 (48)

MGB, Mass General Brigham healthcare system; SD, standard deviation; COVID-19, Coronavirus Disease 2019.

^{*}These authors contributed equally to this work (co-first authors).

[†]These authors contributed equally to this work (co-last authors).

Supplemental Table 2. Risk of death following COVID-19 in patients treated with CD20 inhibitors for rheumatic disease indications versus comparators.

	CD20 Inhibitor- Treated Rheumatic Disease Cases (n=56)*	Matched Comparators (n=276)
Deaths, n (%)	7 (13)	15 (5)
Total follow-up time (person-days)	7917	42560
Incidence rate/1000 days (95% CI)	0.9 (0.2 to 1.5)	0.4 (0.2 to 0.5)
Unadjusted HR (95% CI)	2.52 (1.07 to 5.90)	Ref
Adjusted model 1 HR (95% CI)†	2.42 (1.02 to 5.74)	Ref
Adjusted model 2 HR (95% CI)	2.02 (0.71 to 5.80)	Ref
Adjusted model 3 HR (95% CI)‡	NR	Ref

HR, hazard ratio; CI, confidence interval; BMI, body mass index; CCI, Charlson comorbidity index; Ref, reference; NR, not reported

^{*} Rheumatic disease indication includes 54 patients with rheumatic disease indication only and 2 patients with combined rheumatic and hematologic indications.

[†] Model 1 adjusted for age. Model 2 adjusted for age and race. Model 3 adjusted for age, race, BMI, and CCI (dichotomized as <2 or ≥2).

[‡] Model 3 not reported due to insufficient number of outcomes (<7 outcomes per adjusted covariate).

Supplemental Table 3. Risk of death following COVID-19 in patients treated with CD20 inhibitors for neurologic disease indications versus comparators.

	CD20 Inhibitor- Treated Neurologic Disease Cases (n=43)	Matched Comparators (n=211)
Deaths, n (%)	2 (5)	4 (2)
Total follow-up time (person-days)	6551	34051
Incidence rate/1000 days (95% CI)	0.3 (0.0 to 0.7)	0.1 (0.0 to 0.2)
Unadjusted HR (95% CI)	2.41 (0.66 to 8.77)	Ref
Adjusted model 1 HR (95% CI)*	NR	Ref
Adjusted model 2 HR (95% CI)	NR	Ref
Adjusted model 3 HR (95% CI)	NR	Ref

HR, hazard ratio; CI, confidence interval; BMI, body mass index; CCI, Charlson comorbidity index; Ref, reference; NR, not reported

Supplemental Table 4. Risk of death following COVID-19 in immune-mediated cases treated with CD20 inhibitors for greater than or less than 1 year versus matched comparators.

	< 1 Year of CD20 Inhibitor Exposure		> 1 Year of CD20 Inhibitor Exposure	
	CD20 Inhibitor- Treated Immune- Mediated Cases (n=81)	Matched Comparators (n=399)	CD20 Inhibitor- Treated Immune- Mediated Cases (n=33)	Matched Comparators (n=160)
Deaths, n (%)	7 (9)	11 (3)	5 (15)	10 (6)
Total follow-up time (person-days)	11088	59458	4730	24714
Incidence rate/1000 days (95% CI)	0.6 (0.2 to 1.1)	0.2 (0.1 to 0.3)	1.1 (0.1 to 2.0)	0.4 (0.2 to 0.7)
Unadjusted HR (95% CI)	2.82 (1.34 to 5.96)	Ref	2.92 (0.95 to 8.99)	Ref
Adjusted model 1 HR (95% CI)*	2.85 (1.35 to 6.01)	Ref	2.90 (0.95 to 8.87)	Ref
Adjusted model 2 HR (95% CI)	2.91 (1.26 to 6.74)	Ref	2.02 (0.61 to 6.70)	Ref
Adjusted model 3 HR (95% CI)†	NR	Ref	NR	Ref

HR, hazard ratio; CI, confidence interval; BMI, body mass index; CCI, Charlson comorbidity index; Ref, reference; NR, not reported

^{*} Model 1 adjusted for age. Model 2 adjusted for age and race. Model 3 adjusted for age, race, BMI, and CCI (dichotomized as <2 or ≥2). Adjusted models not reported due to insufficient number of outcomes (<7 outcomes per adjusted covariate).

^{*} Model 1 adjusted for age. Model 2 adjusted for age and race. Model 3 adjusted for age, race, BMI, and CCI (dichotomized as <2 or ≥2).

[†] Model 3 not reported due to insufficient number of outcomes (<7 outcomes per adjusted covariate).

Supplemental Table 5. Risk of death following COVID-19 in patients treated with CD20 inhibitors and not receiving glucocorticoids versus comparators.

	CD20 Inhibitor- Treated Cases (n=79)	Matched Comparators (n=384)
Deaths, n (%)	6 (8)	6 (2)
Total follow-up time (person-days)	11878	61304
Incidence rate/1000 days (95% CI)	0.50 (0.10 to 0.90)	0.10 (0.00 to 0.20)
Unadjusted HR (95% CI)	4.37 (1.79 to 10.71)	Ref
Adjusted model 1 HR (95% CI)*	4.43 (1.79 to 10.98)	Ref
Adjusted model 2 HR (95% CI)†	NR	Ref
Adjusted model 3 HR (95% CI)	NR	Ref

HR, hazard ratio; CI, confidence interval; BMI, body mass index; CCI, Charlson comorbidity index; Ref, reference; NR, not reported

Supplemental Table 6. Risk of death following COVID-19 in patients without cancer treated with CD20 inhibitors versus comparators.

	CD20 Inhibitor- Treated Cases (n=103)	Matched Comparators (n=502)
Deaths, n (%)	11 (11)	19 (4)
Total follow-up time (person-days)	14558	76981
Incidence rate/1000 days (95% CI)	0.80 (0.30 to 1.20)	0.20 (0.10 to 0.40)
Unadjusted HR (95% CI)	3.00 (1.53 to 5.92)	Ref
Adjusted model 1 HR (95% CI)*	2.99 (1.52 to 5.86)	Ref
Adjusted model 2 HR (95% CI)	2.57 (1.21 to 5.45)	Ref
Adjusted model 3 HR (95% CI)	2.20 (1.00 to 4.85)	Ref

HR, hazard ratio; CI, confidence interval; BMI, body mass index; CCI, Charlson comorbidity index.

Supplemental Table 7. Risk of death following COVID-19 in patients without interstitial lung disease treated with CD20 inhibitors versus comparators.

	CD20 Inhibitor-	Matched Comparators
	Treated Cases (n=89)	(n=396)
Deaths, n (%)	6 (7)	7 (2)
Total follow-up time (person-days)	13535	65014
Incidence rate/1000 days (95% CI)	0.40 (0.10 to 0.80)	0.10 (0.00 to 0.20)
Unadjusted HR (95% CI)	3.51 (1.41 to 8.71)	Ref
Adjusted model 1 HR (95% CI)*	3.45 (1.36 to 8.73)	Ref
Adjusted model 2 HR (95% CI)†	NR	Ref
Adjusted model 3 HR (95% CI)	NR	Ref

^{*} Model 1 adjusted for age. Model 2 adjusted for age and race. Model 3 adjusted for age, race, BMI, and CCI (dichotomized as <2 or ≥2).

[†] Models 2 and 3 not reported due to insufficient number of outcomes (<7 outcomes per adjusted covariate).

^{*} Model 1 adjusted for age. Model 2 adjusted for age and race. Model 3 adjusted for age, race, BMI, and CCI (dichotomized as <2 or ≥2).

HR, hazard ratio; CI, confidence interval; BMI, body mass index; CCI, Charlson comorbidity index; Ref, reference; NR, not reported

- * Model 1 adjusted for age. Model 2 adjusted for age and race. Model 3 adjusted for age, race, BMI, and CCI (dichotomized as <2 or ≥2).
- † Models 2 and 3 not reported due to insufficient number of outcomes (<7 outcomes per adjusted covariate).

Supplemental Table 8. Risk of death following COVID-19 in patients treated with most recent CD20 inhibitor dose within 3 months of COVID-19 infection versus comparators.

	CD20 Inhibitor- Treated Cases (n=48)	Matched Comparators (n=235)
Deaths, n (%)	7 (15)	6 (3)
Total follow-up time (person-days)	6099	34753
Incidence rate/1000 days (95% CI)	1.10 (0.30 to 2.00)	0.20 (0.00 to 0.30)
Unadjusted HR (95% CI)	9.59 (2.98 to 30.85)	Ref
Adjusted model 1 HR (95% CI)*	9.79 (3.00 to 31.93)	Ref
Adjusted model 2 HR (95% CI)†	NR	Ref
Adjusted model 3 HR (95% CI)	NR	Ref

HR, hazard ratio; CI, confidence interval; BMI, body mass index; CCI, Charlson comorbidity index; Ref, reference; NR, not reported

****POTENTIAL Supplemental Table 9. Immune-mediated disease status at the time of COVID-19 diagnosis by timing of most recent rituximab dose prior to infection. ****

	Most recent	Most recent CD20	Most recent	P-value
	CD20 inhibitor	inhibitor dose 3-6	CD20 inhibitor	
	dose < 3	months prior to	dose 6-12	
	months prior to	COVID-19 (n=44)	months prior to	
	COVID-19		COVID-19	
	(n=48)		(n=22)	
Immune-mediated				0.23
disease status				
Remission	13 (27)	7 (16)	<mark>6 (27)</mark>	
Low activity	<mark>19 (40)</mark>	28 (64)	<mark>11 (50)</mark>	
Moderate/high activity	16 (33)	9 (20)	5 (23)	

Number of death	Most recent CD20	Most recent CD20	Most recent CD20
	inhibitor dose < 3	inhibitor dose 3-6	inhibitor dose 6-12
	months prior to	months prior to	months prior to
	COVID-19 (n=48)	COVID-19 (n=44)	COVID-19 (n=22)
Immune-mediated disease			
status			
Remission	1 (2)	<mark>1 (2)</mark>	0 (0)

^{*} Model 1 adjusted for age. Model 2 adjusted for age and race. Model 3 adjusted for age, race, BMI, and CCI (dichotomized as <2 or ≥2).

[†] Models 2 and 3 not reported due to insufficient number of outcomes (<7 outcomes per adjusted covariate).

Low activity	1 (2)	2 (4)	0 (0)
Moderate/high activity	5 (10)	1 (2)	1 (5)